# Diabetes Research Hub — Monitor Review Report

**Run date:** 2026-06-04 (automated, scheduled)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot diffs, and a 7-day web scan.
**Reviewer note:** This is a read-only review run. No existing files were modified. New claims below are tagged with evidence levels per RESEARCH_DOCTRINE.md.

---

## File System Status

Core data files are fresh (refreshed this morning, 2026-06-04 07:04–07:05):

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-06-04 07:04 | ✅ Current |
| pubmed_recent_latest.json | 2026-06-04 07:05 | ✅ Current |
| hub_monitor_report.md | 2026-06-04 07:05 | ✅ Current |
| clinical_trials_summary.md | 2026-06-04 07:04 | ✅ Current |
| pubmed_recent_summary.md | 2026-06-04 07:05 | ✅ Current |
| literature_gap_report.md | 2026-06-03 08:07 | ✅ Current (1 day) |
| literature_gap_data.json | **2026-04-20 15:35** | ⚠️ **Stale (45 days)** |

**Hub totals (from hub_monitor.py):** 894 files tracked — 3 new, 28 modified, 0 removed since yesterday. The monitor flags 674 result files older than 14 days; most are dated daily snapshots, which is expected and not actionable.

**Action item:** The gap analysis *report* (`literature_gap_report.md`) was regenerated 2026-06-03, but the underlying `literature_gap_data.json` it nominally derives from is dated 2026-04-20. Confirm the Jun 3 report actually re-queried PubMed, or re-run `project1_literature_gap_analysis.py` to refresh the data file so the two stay in sync.

---

## Clinical Trial Changes

**Snapshot diff (2026-06-03 → 2026-06-04):** 1 new trial, 0 removed, 1 status change, 0 newly-posted results in the daily diff. Totals: 801 unique trials (263 RECRUITING, 134 NOT_YET_RECRUITING, 108 ACTIVE_NOT_RECRUITING, 289 COMPLETED).

### New trial since yesterday
- **NCT05813912** (Novo Nordisk, Phase 3, COMPLETED) — Once-weekly insulin icodec given alone. Entered the dataset because results were posted 2026-06-03 (it moved into the "recently completed with results" category).

### Status change
- **NCT07303803** — Chiglitazar in MASH (metabolic dysfunction-associated steatohepatitis): NOT_YET_RECRUITING → **RECRUITING**.

### Recently posted results (last 7 days) worth a look
| NCT ID | Posted | Sponsor | Topic |
|--------|--------|---------|-------|
| NCT05813912 | 2026-06-03 | Novo Nordisk | Once-weekly insulin icodec monotherapy (Phase 3) |
| NCT05925920 | 2026-06-01 | Metabolics Pharma | ENT-03 (subcutaneous) for diabetes |
| NCT05014789 | 2026-06-01 | Tandem Diabetes Care | Control-IQ 2.0 adult/adolescent feasibility |
| NCT04227379 | 2026-06-01 | VA ORD | Texting intervention for diabetes disparities |
| NCT05301478 | 2026-06-01 | VA ORD | 3D-printed diabetic insoles |
| NCT06728059 | 2026-05-28 | Sue Brown (UVA) | ML bolus-priming algorithm (closed loop) |

### Key Phase 3 trials from priority organizations (current status)
There are 46 Phase 3 RECRUITING trials and 59 trials from key sponsors (Vertex, Lilly, Novo Nordisk, Sana). Highlights:

- **Vertex zimislecel / VX-880** (islet cell therapy, T1D): NCT04786262 and NCT06832410 — both **Phase 3 RECRUITING**. VX-264 (encapsulated, NCT05791201) remains Phase 1/2 ACTIVE_NOT_RECRUITING.
- **Eli Lilly baricitinib** (T1D beta-cell preservation): NCT07222332 (preserve beta-cell function in children) and NCT07222137 (delay Stage 3 T1D) — both **Phase 3 RECRUITING**. Notable: a JAK inhibitor being pushed into T1D prevention/preservation.
- **Sanofi teplizumab**: NCT07088068 — Phase 3 RECRUITING, teplizumab head-to-head comparison.
- **Novo Nordisk insulin icodec (Awiqli)**: NCT07076199 Phase 3 RECRUITING; NCT05813912 just posted results (above).
- **Novo Nordisk CagriSema**: large Phase 3 program active (NCT07564414 RECRUITING; NCT06534411 ACTIVE_NOT_RECRUITING; plus NOT_YET_RECRUITING expansions).
- **Eli Lilly orforglipron** (oral GLP-1): NCT06993792 / NCT06972472 ACTIVE_NOT_RECRUITING; NCT07613307 NOT_YET_RECRUITING (Phase 3).
- **Eli Lilly retatrutide**: NCT06260722 (vs semaglutide), NCT05929079, NCT06297603 — Phase 3 ACTIVE_NOT_RECRUITING.

*No new Vertex/Lilly/Novo/Sana trial appeared in today's diff; the items above are the standing watch-list state.*

---

## PubMed Highlights

**Latest pull (30-day lookback, 2026-06-04):** 162 unique papers across 16 alert domains. Daily diff vs 2026-06-03: 32 new papers, 33 dropped (rolling window).

### Cross-domain papers (highest priority — appear in ≥2 alert domains)
Two are **new today**:

- **[42235729]** *Novel biomarkers of diabetic kidney disease in type 1 diabetes.* — Diabetes Biomarker × Diabetes Complications **(NEW)**
- **[42232971]** *Glycosylation gene-based molecular recognition model for diabetic retinopathy.* — Diabetes Biomarker × Diabetes Complications **(NEW)**

Other notable cross-domain papers in the current window:
- **[42230773]** Integrative analysis of transcriptional regulatory functions of risk variants — AI/ML × Gene Therapy *(aligns with Tier 1 Multi-Omics)*
- **[42228639]** Proteomic signatures of early retinal neurodegeneration in T2D — AI/ML × Biomarker
- **[42225355]** Retinal vasculature-derived proteins as systemic biomarkers — Biomarker × Complications
- **[42219961]** Multi-omics Mendelian randomization, lipid metabolism — Epigenetics × Multi-Omics *(Tier 1 Multi-Omics)*
- **[42163482]** Extracellular vesicle proteins as predictive biomarkers — T1D Stem Cell Cure × T1D Immunotherapy × teplizumab

### Key-therapy mentions
Therapy hit counts (30-day): dapagliflozin 53, retatrutide 10, CagriSema 6, teplizumab 6, icodec 6, orforglipron 4, baricitinib 3, **zimislecel 0**. Specific papers of note:
- **[42221148]** Efficacy and safety of teplizumab in Stage 3 T1D treatment.
- **[42138080]** New and emerging therapies in T1D (review, teplizumab).
- **[42228334]** CagriSema PK/safety unaffected by renal/hepatic impairment.
- **[42198313]** Diabetes & stroke review covering orforglipron + retatrutide + CagriSema.

### Publication volume trends
Highest-activity domains this window: AI/ML (224 total hits), Biomarker (172), T2D GLP-1 New (156), Microbiome (145). Lowest: GLP-1 Pharmacogenomics (3), Drug Repurpose (5), LADA (9) — consistent with these being genuinely small fields, reinforcing the gap-analysis findings below. Zimislecel returning 0 hits despite an active Vertex Phase 3 program suggests results are still pre-publication (worth re-checking around the ADA Scientific Sessions, see Breaking News).

---

## Gap Analysis Summary

**Source:** `literature_gap_report.md` (2026-06-03). Validation level **BRONZE** — single analytical source, expert confirmation pending.

### Top 5 under-researched intersections (highest gap scores)
1. **Beta Cell Regen × Health Equity** — Gap 100.0, 0 joint pubs. Equity analysis of emerging cell therapies is absent.
2. **Insulin Resistance × Islet Transplant** — Gap 100.0, 1 joint pub. IR in graft recipients affects survival but is barely studied.
3. **Islet Transplant × Drug Repurposing** — Gap 100.0, 0 joint pubs. No computational screening of existing drugs for islet protection.
4. **Islet Transplant × Health Equity** — Gap 100.0, 0 joint pubs. Access equity for a select-center-only therapy is unstudied.
5. **Gene Therapy × LADA** — Gap 100.0, 0 joint pubs. No crossover work despite LADA's autoimmune mechanism.

### Alignment with Tier 1 contribution areas (RESEARCH_DOCTRINE.md)
Several top gaps sit directly in our Tier 1 lanes and are strong candidates for computational contribution:
- **Drug Repurposing** (Tier 1 #4): gaps #3 (Islet Transplant × Drug Repurposing), plus Glucokinase × Drug Repurposing and Drug Repurposing × LADA. These are actionable with OpenTargets/STRING network screens.
- **Health Equity / Epidemiology** (Tier 1 #6): gaps #1 and #4, plus Treg/CAR-T × Health Equity and Drug Repurposing × Health Equity — addressable with public disparity datasets.
- **Multi-Omics Biomarker Integration** (Tier 1 #1): reinforced by today's cross-domain biomarker papers (42235729, 42219961, 42228639).

**Caveat (per Doctrine):** these are keyword-based PubMed gap scores. Before acting, verify each is a real gap and not a terminology artifact, and cross-check Cochrane/PROSPERO for existing reviews.

---

## Breaking News (7-day web scan)

- **ADA 2026 Scientific Sessions, June 5–8, New Orleans** — starts tomorrow. >12,000 attendees; programming centers on beta-cell replacement, regenerative medicine, immune-based therapies, and AI in care. **High priority:** expect a wave of Phase 3 readouts and late-breakers (likely including Vertex zimislecel, Lilly orforglipron/retatrutide, Novo CagriSema). Plan to re-run trial + PubMed pulls right after the conference.
- **Lab-grown insulin-producing cells (Sweden, *Stem Cell Reports*)** — a more reliable method to derive insulin-producing cells from human stem cells; reversed diabetes in mice. Preclinical (Evidence Level: low / animal model), but thematically central to the T1D cure track.
- **Regulatory context (2026 to date, not new this week):** oral semaglutide (Ozempic tablets) approved Feb 2026; Awiqli/insulin icodec once-weekly basal approved Mar 26 2026; first generic dapagliflozin approved Apr 7 2026; Langlara (insulin glargine biosimilar) approved Apr 29 2026. No *new* FDA diabetes approval surfaced in the last 7 days.

No genuinely new Phase 3 result or FDA action was confirmed in the past week — but the ADA Sessions will likely change that within days.

---

## Recommended Actions

1. **Refresh gap data file.** `literature_gap_data.json` is 45 days old while its report is 1 day old. Run `python project1_literature_gap_analysis.py` to resync, or confirm the report's data provenance.
2. **Schedule a post-ADA refresh.** The Scientific Sessions (Jun 5–8) will produce late-breaking Phase 3 results. Re-run `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py` on ~Jun 9 to capture readouts.
3. **Watch zimislecel publications.** 0 PubMed hits despite two active Vertex Phase 3 trials (NCT04786262, NCT06832410). First efficacy publications likely around/after ADA — flag for review.
4. **Review the 2 new cross-domain papers** (Biomarker × Complications): PMID 42235729 (DKD biomarkers in T1D) and 42232971 (glycosylation-gene model for retinopathy) — both relevant to Tier 1 Multi-Omics Biomarker work.
5. **Update the tracker** with the new icodec results readout (NCT05813912) and the Chiglitazar MASH status change (NCT07303803 → RECRUITING).
6. **Prioritize a Tier-1-aligned gap** for the next computational deep-dive: *Islet Transplant × Drug Repurposing* (gap #3) is the cleanest fit for a network-pharmacology screen using already-available tooling.

---
*Generated by the Diabetes Research Hub automated monitor — read-only review. New scientific claims tagged BRONZE/low-evidence per Research Doctrine v1.0.*
